Active Research Protocols
- 10-C-0181 – Phase 1 Dose-Escalation Study of BrutonÕs Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Recurrent B Cell Lymphoma
- 11-C-0162 – A Multicenter, Open-Label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory De Novo Diffuse Large B-Cell Lymphoma
NOTE: PDF documents require the freeAdobe Reader.
This page was last updated: January 24, 2014